Literature DB >> 17260465

[Effect of urotensin II on proliferative potential and phosphorylation of extracellular signal-regulated kinase 1/2 of adventitial fibroblasts from spontaneously hypertensive rat].

Hong-yan Dai1, Zhi-ming Ge, Yong-hong Li.   

Abstract

OBJECTIVE: To study the effect of urotensin II ( U II ) on the proliferative potential of adventitial fibroblasts (AFs) from spontaneously hypertensive rat (SHR) and to determine whether extracellular signal-regulated kinase 1/2 (ERK1/2) pathway is involved in this progress.
METHODS: 3H-thymidine incorporation test was used to estimate the U II -induced proliferative potential of AFs from SHR and the influence of Urantide (U II receptor antagonist) and PD98059 (ERK1/2 inhibitor). Western blotting was used to test the U II -induced ERK1/2 phosphorylation as well as the effect of Urantide and PD98059 on U II -induced ERKl/2 phosphorylation.
RESULTS: U 11 increased the proliferative potential of AFs from SHR in a dose-dependent way. Urantide and PD98059 wholly or partly inhibited U II -induced proliferation of SHR-AFs. In SHR-AFs, U II induced the phosphorylation of ERK1/2 in a time-dependent way, which was completely inhibited by Urantide and PD98059.
CONCLUSION: U II can increase the proliferative potential of AFs from SHR and ERK1/2 pathway is partly involved in this progress.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17260465

Source DB:  PubMed          Journal:  Zhongguo Yi Xue Ke Xue Yuan Xue Bao        ISSN: 1000-503X


  2 in total

1.  Protein expression of urotensin II, urotensin-related peptide and their receptor in the lungs of patients with lymphangioleiomyomatosis.

Authors:  Arnold S Kristof; Zhipeng You; Yin-Shan Han; Adel Giaid
Journal:  Peptides       Date:  2010-04-28       Impact factor: 3.750

2.  Moxibustion Inhibits the ERK Signaling Pathway and Intestinal Fibrosis in Rats with Crohn's Disease.

Authors:  Xiaomei Wang; Yuan Lu; Luyi Wu; Chen Zhao; Chunbin Song; Shuguang Yu; Baixiao Zhao; Tianping Zhao; Huirong Liu; Chuanzi Dou; Yingying Zhang; Huangan Wu
Journal:  Evid Based Complement Alternat Med       Date:  2013-07-22       Impact factor: 2.629

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.